Madera Therapeutics is the pioneer and leader in small-molecule ClpP agonist drug development, having recognized and operationalized this novel mitochondrial target years before clinical validation. Madera has built the field’s most comprehensive global patent estate covering potent, next-generation ClpP agonists with activity across drug-resistant and refractory cancers. The biology and chemistry are supported by multiple peer-reviewed publications from leading academic groups and the U.S. National Cancer Institute, which is advancing Madera-derived compounds toward clinical evaluation. New UNC data (Der) highlight TR-107 activity and additivity in KRAS-inhibitor combinations, including resistant settings.